These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 39045273

  • 21. BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma.
    Lim AM, Taylor GR, Fellowes A, Cameron L, Lee B, Hicks RJ, McArthur GA, Angel C, Solomon B, Rischin D.
    J Natl Compr Canc Netw; 2016 Mar; 14(3):249-54. PubMed ID: 26957611
    [Abstract] [Full Text] [Related]

  • 22. Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer.
    Fazeli S, Paal E, Maxwell JH, Burman KD, Nylen ES, Khosla SG.
    J Investig Med High Impact Case Rep; 2019 Mar; 7():2324709619890942. PubMed ID: 31766881
    [Abstract] [Full Text] [Related]

  • 23. Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma.
    Yang S, Ji D, Xue F, Chen T, Wang Y, Ji Q.
    Cancer Rep (Hoboken); 2023 Jan; 6(1):e1770. PubMed ID: 36535914
    [Abstract] [Full Text] [Related]

  • 24. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
    Iñiguez-Ariza NM, Ryder MM, Hilger CR, Bible KC.
    Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
    [Abstract] [Full Text] [Related]

  • 25. Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement.
    Hamidi S, Dadu R, Zafereo ME, Ferrarotto R, Wang JR, Maniakas A, Gunn GB, Lee A, Spiotto MT, Iyer PC, Sousa LG, Akhave NS, Ahmed S, Learned KO, Lu C, Lai SY, Williams M, Hosseini SM, Busaidy NL, Cabanillas ME.
    JAMA Oncol; 2024 Sep 01; 10(9):1264-1271. PubMed ID: 38990526
    [Abstract] [Full Text] [Related]

  • 26. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
    Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski CC, Cabanillas ME, Boran A, Ilankumaran P, Burgess P, Romero Salas T, Keam B.
    Ann Oncol; 2022 Apr 01; 33(4):406-415. PubMed ID: 35026411
    [Abstract] [Full Text] [Related]

  • 27. Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.
    Califano I, Smulever A, Jerkovich F, Pitoia F.
    Rev Endocr Metab Disord; 2024 Feb 01; 25(1):123-147. PubMed ID: 37648897
    [Abstract] [Full Text] [Related]

  • 28. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
    Xu B, Fuchs T, Dogan S, Landa I, Katabi N, Fagin JA, Tuttle RM, Sherman E, Gill AJ, Ghossein R.
    Thyroid; 2020 Oct 01; 30(10):1505-1517. PubMed ID: 32284020
    [Abstract] [Full Text] [Related]

  • 29. Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.
    da Silva TN, Rodrigues R, Saramago A, Pires C, Rito M, Horta M, Martins C, Leite V, Cavaco BM.
    Eur J Endocrinol; 2023 Jan 10; 188(1):. PubMed ID: 36651156
    [Abstract] [Full Text] [Related]

  • 30. BRAFV600E Overrides NOTCH Signaling in Thyroid Cancer.
    Traversi F, Stooss A, Dettmer MS, Charles RP.
    Thyroid; 2021 May 10; 31(5):787-799. PubMed ID: 33012268
    [Abstract] [Full Text] [Related]

  • 31. Laryngotracheal Resection After B-Raf Proto-oncogene Inhibition for Anaplastic Thyroid Carcinoma.
    Kent J, Erwin P, Haraf D, Liao CY, Durham J, Angelos P, Agrawal N, Baird BJ, Madariaga MLL.
    Ann Thorac Surg; 2023 May 10; 115(5):e117-e120. PubMed ID: 35504360
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis.
    Priantti JN, Rodrigues NMV, de Moraes FCA, da Costa AG, Jezini DL, Heckmann MIO.
    Endocrine; 2024 Oct 10; 86(1):284-292. PubMed ID: 38709445
    [Abstract] [Full Text] [Related]

  • 33. Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Preliminary Latin American Experience.
    Pitoia F, Abelleira E, Román-González A, Danilovic DLS, Scheffel RS, Maia AL, Hoff AO, Califano I.
    Thyroid; 2024 Jul 10; 34(7):949-952. PubMed ID: 38757613
    [Abstract] [Full Text] [Related]

  • 34. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
    Di Desidero T, Orlandi P, Gentile D, Banchi M, Alì G, Kusmic C, Armanetti P, Cayme GJ, Menichetti L, Fontanini G, Francia G, Bocci G.
    Pharmacol Res; 2020 Aug 10; 158():104920. PubMed ID: 32461187
    [Abstract] [Full Text] [Related]

  • 35. Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature.
    Arıkan R, Telli TA, Demircan NC, Başoğlu T, Ercelep Ö, Atasoy BM, Özgüven S, Dane F, Yumuk PF.
    Curr Probl Cancer; 2021 Apr 10; 45(2):100668. PubMed ID: 33127167
    [Abstract] [Full Text] [Related]

  • 36. A long survival patient of anaplastic thyroid carcinoma treated with lenvatinib.
    Hamamoto T, Kono T, Taruya T, Ishino T, Ueda T, Takeno S.
    Auris Nasus Larynx; 2022 Jun 10; 49(3):515-519. PubMed ID: 33109426
    [Abstract] [Full Text] [Related]

  • 37. Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.
    Teng L, Deng W, Lu J, Zhang J, Ren X, Duan H, Chuai S, Duan F, Gao W, Lu T, Wu H, Liang Z.
    Oncotarget; 2017 Mar 28; 8(13):22023-22033. PubMed ID: 28423545
    [Abstract] [Full Text] [Related]

  • 38. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
    Jeon MJ, Chun SM, Kim D, Kwon H, Jang EK, Kim TY, Kim WB, Shong YK, Jang SJ, Song DE, Kim WG.
    Thyroid; 2016 May 28; 26(5):683-90. PubMed ID: 26980298
    [Abstract] [Full Text] [Related]

  • 39. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.
    Charles RP, Silva J, Iezza G, Phillips WA, McMahon M.
    Mol Cancer Res; 2014 Jul 28; 12(7):979-86. PubMed ID: 24770869
    [Abstract] [Full Text] [Related]

  • 40. Pathologic complete response after neoadjuvant v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibition combined with immunotherapy therapy for anaplastic thyroid carcinoma: a case report and literature review.
    Song Y, Bai Y, Wang J, Xu G, Wang T, Zhang B.
    Endocr J; 2023 Feb 28; 70(2):223-228. PubMed ID: 36351596
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.